{"id":"clearcare","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ClearCare reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"ClearCare is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:12.430Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02537730","phase":"NA","title":"BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study","status":"COMPLETED","sponsor":"CooperVision, Inc.","startDate":"2015-09","conditions":"Myopia","enrollment":33},{"nctId":"NCT02196766","phase":"NA","title":"BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens","status":"COMPLETED","sponsor":"CooperVision, Inc.","startDate":"2014-07","conditions":"Myopia","enrollment":30},{"nctId":"NCT01335750","phase":"NA","title":"A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand","status":"COMPLETED","sponsor":"CooperVision, Inc.","startDate":"2010-08","conditions":"Corneal Staining","enrollment":32},{"nctId":"NCT01233089","phase":"NA","title":"Fitting Children With Contact Lenses","status":"COMPLETED","sponsor":"CIBA VISION","startDate":"2010-09","conditions":"Refractive Error","enrollment":194},{"nctId":"NCT01629706","phase":"NA","title":"Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers","status":"COMPLETED","sponsor":"CIBA VISION","startDate":"2012-09","conditions":"Refractive Error, Dry Eye","enrollment":92},{"nctId":"NCT01198600","phase":"NA","title":"Ocular Comfort and the \"Aging\" Lens (ERBIUM)","status":"COMPLETED","sponsor":"CIBA VISION","startDate":"2010-07","conditions":"Refractive Error","enrollment":78},{"nctId":"NCT00520351","phase":"PHASE3","title":"Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2007-08","conditions":"Myopia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ClearCare","genericName":"ClearCare","companyName":"University of Waterloo","companyId":"university-of-waterloo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ClearCare is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}